Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Qualcomm Incorporated stock logo
QCOM
Qualcomm
$168.52
-2.3%
$178.73
$121.99
▼
$259.92
$189.54B1.713.86 million shs11.82 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$952.40
-0.3%
$818.67
$591.52
▼
$991.73
$98.40B0.1984,019 shs700,567 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Qualcomm Incorporated stock logo
QCOM
Qualcomm
-2.29%-1.72%-2.09%+5.20%-3.14%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-0.32%+3.53%+20.44%+17.55%+37.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Qualcomm Incorporated stock logo
QCOM
Qualcomm
$168.52
-2.3%
$178.73
$121.99
▼
$259.92
$189.54B1.713.86 million shs11.82 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$952.40
-0.3%
$818.67
$591.52
▼
$991.73
$98.40B0.1984,019 shs700,567 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Qualcomm Incorporated stock logo
QCOM
Qualcomm
-2.29%-1.72%-2.09%+5.20%-3.14%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-0.32%+3.53%+20.44%+17.55%+37.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Qualcomm Incorporated stock logo
QCOM
Qualcomm
2.43
Hold$197.1316.98% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.74
Moderate Buy$898.97-5.61% Downside

Current Analyst Ratings Breakdown

Latest QCOM and REGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/11/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
UpgradeStrong Sell ➝ Hold
11/9/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
UpgradeHold (C) ➝ Buy (B-)
11/9/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
DowngradeBuy ➝ Hold$200.00 ➝ $185.00
11/5/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Reiterated RatingNeutral
11/5/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Set Price Target$320.00
11/5/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Lower Price TargetUnderweight$180.00 ➝ $150.00
11/5/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Reiterated RatingNeutral
11/5/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Lower Price TargetNeutral$185.00 ➝ $180.00
11/5/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Lower Price TargetNeutral$215.00 ➝ $200.00
11/5/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
Lower Price TargetBuy$200.00 ➝ $185.00
11/2/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UpgradeHold (C) ➝ Hold (C+)
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Qualcomm Incorporated stock logo
QCOM
Qualcomm
$43.12B4.18$8.85 per share19.05$28.41 per share5.93
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.34B6.87$42.03 per share22.66$323.82 per share2.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Qualcomm Incorporated stock logo
QCOM
Qualcomm
$13.63B$12.7013.2718.602.0731.60%30.62%14.53%2/3/2027 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.50B$45.2921.0315.171.2628.51%16.01%12.22%1/28/2027 (Estimated)

Latest QCOM and REGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q4 2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
$2.16$2.17+$0.01$1.17$10.12 billion$10.44 billion
10/30/2026Q3 2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$16.51$20.07+$3.56$18.45$4.58 billion$5.12 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Qualcomm Incorporated stock logo
QCOM
Qualcomm
$3.682.18%+6.36%28.98%23 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.760.39%N/A8.30%N/A

Latest QCOM and REGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/8/2026
Qualcomm Incorporated stock logo
QCOM
Qualcomm
quarterly$0.922.07%12/3/202612/3/202612/17/2026
10/30/2026
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.940.41%11/20/202611/20/202612/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Qualcomm Incorporated stock logo
QCOM
Qualcomm
0.42
1.86
1.14
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.06
3.35
2.89

Institutional Ownership

CompanyInstitutional Ownership
Qualcomm Incorporated stock logo
QCOM
Qualcomm
74.35%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
Qualcomm Incorporated stock logo
QCOM
Qualcomm
0.05%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6.97%
CompanyEmployeesShares OutstandingFree FloatOptionable
Qualcomm Incorporated stock logo
QCOM
Qualcomm
57,0001.07 billion1.07 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,410103.45 million96.24 millionOptionable

Recent News About These Companies

REGN Price Forecast: Rally Faces Resistance After 37% Advance
Regeneron touts positive POTS Phase II results for baloncibart
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?
Citi Sticks to Its Hold Rating for Regeneron (REGN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Qualcomm stock logo

Qualcomm NASDAQ:QCOM

$168.52 -3.95 (-2.29%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$170.63 +2.11 (+1.25%)
As of 07:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Qualcomm Incorporated engages in the development and commercialization of foundational technologies for the wireless industry worldwide. It operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on 3G/4G/5G and other technologies for use in wireless voice and data communications, networking, computing, multimedia, and position location products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of wireless products comprising products implementing CDMA2000, WCDMA, LTE and/or OFDMA-based 5G standards and their derivatives. The QSI segment invests in early-stage companies in various industries, including 5G, artificial intelligence, automotive, consumer, enterprise, cloud, IoT, and extended reality, and investments, including non-marketable equity securities and, to a lesser extent, marketable equity securities, and convertible debt instruments. It also provides development, and other services and related products to the United States government agencies and their contractors. The company was incorporated in 1985 and is headquartered in San Diego, California.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$952.40 -3.07 (-0.32%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$951.46 -0.94 (-0.10%)
As of 07:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.